Clinical trials: Graft -Versus-host-disease
Chronic Rhinosinusitis
Canadian Health Economics, Outcome, and Effectiveness Comparison of Treatment in Patients With Chronic Rhinosinusitis
The economic, patient related outcome, and effectiveness of balloon sinuplasty in the treatment of CRS patients with frontal and other sinus disease in the Canadian healthcare environment is not known at this time.
- Trial name
- CHEC (NCT01455948)
- Testing
- Relieva Balloon Sinuplasty™ System, Functional Endoscopic Sinus Surgery
- Where
- 8 sites in Canada
- Volunteers
- 25 people
- Sponsor
- Integra LifeSciences Corporation
Graft-versus-host-disease, CMV
Letermovir Prophylaxis for Cytomegalovirus (CMV) in Patients With Graft-versus-host Disease
Explore the tolerability and efficacy of letermovir in the prevention of CMV reactivation in patients with acute and chronic graft-versus-host disease (GVHD) beyond day 100.
- Trial name
- NCT05969743
- Testing
- Letermovir
- Volunteers
- 42 people
- Sponsor
- Rabin Medical Center
Allograft
Feasibility Study of Platelet Activation and Inflammatory Response of Platelets in Hematopoietic Stem Cell Allograft Patients Post-transplant: Spontaneously and After Stimulation by an CMV Antigen
Traditionally known for their role in haemostasis, platelets have also an immune role. Platelets play a key role in immune mediator secretion, and interact with innate and adaptive immune cells, contributing to the fight against…
- Trial name
- FIPALLOC (NCT03009708)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Institut de Cancérologie de la Loire
Atopic Dermatitis, Contact Dermatitis
Exploratory Study of Natural Killer Cells in Human Skin
Natural Killer (NK) cells play a unique role during innate immune responses as they are able to recognize and eliminate, without specific sensitization, tumors, microbe-infected cells as well as allogeneic cells.In a first time…
- Conditions
- Atopic Dermatitis, Contact Dermatitis, Psoriasis, Lichen Planus
- Trial name
- NCT00824889
- Testing
- Biopsy and sample of blood
- Where
- France
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Graft Versus Host Disease
Sequential Administration of WJ-MSCs for the Treatment of GvHD Refractory to Second Line Treatment
Hematopoietic stem cell transplantation (HSCT) is the treatment of choice for malignant hemopathies, but highlights the limitations of long-term results due to the high toxicity of the procedure and the development of Graft…
- Trial name
- GvHD (NCT06304025)
- Testing
- Wharton's jelly mesenchymal stem cells (WJ-MSCs)
- Volunteers
- 10 people
- Sponsor
- Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle
Acute Leukemia, Myelodysplasia
ATG Plus PTCy vs ATG for CGVHD Prophylaxis
A Randomized Pilot Trial to test the feasibility of comparing anti-thymocyte globulin plus post transplant cyclophosphamide with anti-thymocyte globulin alone to prevent chronic graft versus host disease.
- Conditions
- Acute Leukemia, Myelodysplasia, Chronic Graft-versus-host-disease
- Trial name
- NCT04202835
- Testing
- Cyclophosphamide, Anti-Thymocyte globulin (rabbit)
- Where
- 9 sites in Australia, Canada
- Volunteers
- 80 people
- Sponsor
- McMaster University
Chronic Pain
Chronic Pain Management After Herniorraphy
Nowadays, chronic pain mainly as a result of iatrogenic nerve damage is generally considered as the most frequent complication after inguinal hernia surgery.
- Trial name
- pregabalin (NCT00772291)
- Testing
- pregabalin
- Where
- Netherlands
- Volunteers
- 140 people
- Sponsor
- Erasmus Medical Center
Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease
Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)
The study compares two acute graft-versus-host disease (aGVHD) prophylaxis regimens: efprezimod alfa vs placebo with the standard GVHD prophylaxis of tacrolimus / methotrexate.
- Conditions
- Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- CATHY (NCT04095858)
- Testing
- Efprezimod alfa, Methotrexate, Tacrolimus
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Graft Versus Host Disease, Bone Marrow Transplantation
Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants
Graft versus host disease (GVHD) is one of the common complications after stem cell transplant. This is a complication, which happens when the new stem cells from the donor attack other cells in the body of the transplant…
- Trial name
- NCT00775632
- Testing
- Alemtuzumab, mycophenolate or cyclosporine and methotrexate
- Where
- Canada
- Volunteers
- 78 people
- Sponsor
- University Health Network, Toronto
Poor Graft Function, Stem Cell Transplantation
G-CSF Moblized Peripheral Harvest for Poor Engraftment After Stem Cell Transplantation
Poor graft function (PGF) is a common complication after allogeneic stem cell transplantation, which was associated with high mortality. The pathogenesis fo PGF was poorly understood.
- Conditions
- Poor Graft Function, Stem Cell Transplantation, Graft Versus Host Disease
- Trial name
- NCT01857336
- Testing
- infusion of G-CSF mobilized peripheral harvest
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University People's Hospital
COVID-19, SARS-CoV-2 Infection
Physical and Cognitive Impairments in People Suffering From Long COVID
Of the 1,900,000 Canadians who have been infected by COVID-19, 8 to 15% will continue to experience COVID-19 related symptoms well after 12 weeks. The persistence of such symptoms is now defined as "long COVID" syndrome.
- Conditions
- COVID-19, SARS-CoV-2 Infection, Corona Virus Infection, Physical Disability
- Trial name
- NCT05216536
- Testing
- No intervention
- Where
- Canada
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Laval University
Medication Overuse Headache
Medication-overuse Headache: 4 Years Follow up
From 1 January 2004 to 31 December 2006 64 individuals with probable medication overuse headache were included in a randomized, 1-year open-labeled, multicentre study to evaluate the effect of early introduction of prophylactic…
- Trial name
- MOHfollowup (NCT00918671)
- Testing
- No new specific intervention
- Where
- Norway
- Volunteers
- 60 people
- Sponsor
- Norwegian University of Science and Technology
Wound
Evaluation of the Safety and Effectiveness of ALLEVYN Gentle Border
The clinical study will evaluate the safety and effectiveness of the ALLEVYN Gentle Border. The study is a post-market clinical follow-up to assess clinical performance and safety of ALLEVYN Gentle Border with new wound contact…
- Trial name
- NCT03877484
- Testing
- ALLEVYN Gentle border
- Where
- 6 sites in France, Germany and 1 more
- Volunteers
- 43 people
- Sponsor
- Smith & Nephew Orthopaedics AG
Lung Transplantation Rejection
Prospective Lung Transplant Database for Genetic Research
This study will create a database of clinical and biological research for use in future studies, with information obtained from lung transplant recipients.
- Trial name
- NCT00339209
- Where
- 2 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Steroid-refractory Acute Graft-versus-host Disease(SR-aGVHD)
A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD
A study to evaluate the safety and preliminary efficacy of iMSC in subjects with SR-aGVHD
- Trial name
- NCT06321198
- Testing
- iMSC
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Anhui Provincial Hospital
Tourette's Disorder, Persistent (Chronic) Motor or Vocal Tic Disorder
TicHelper: A Computerized Comprehensive Behavioral Intervention for Tics (CBIT)
Tic Disorders (including Tourette Disorder) are relatively common in school-age children and for some children can lead to significant psychosocial and physical impairment and diminished quality of life.
- Trial name
- NCT02413216
- Testing
- TicHelper, Internet Based Resources
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- University of Utah
Heart Transplantation
SCHEDULE Follow Up Visit 5-7 yr
The major aim of this extension study was to evaluate the long-term effect (i.e. 5 to 7 years) of early initiation of everolimus and early elimination of CsA compared to standard immunosuppressive regimen including CsA on primary…
- Trial name
- CRAD001ANO05 (NCT02864706)
- Testing
- Everolimus, Cyclosporine, Mycophenolate mofetil
- Where
- 6 sites in Denmark, Norway and 1 more
- Volunteers
- 95 people
- Sponsor
- Novartis Pharmaceuticals
Graft-Versus-Host Disease(GVHD)
5-Azacytidine With Steroids for Gastrointestinal GVHD (5-AZA FOR GVHD)
This study aims to evaluate the safety and feasibility of administering AZA in conjunction with steroids as first line therapy for GI GVHD.
- Trial name
- NCT06598332
- Testing
- 5-Azacytidine
- Where
- 2 sites in United States
- Sponsor
- Baylor College of Medicine
Chronic Lymphocytic Leukemia
Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia
The treatment combination of Rituxan® (rituximab) and fludarabine has previously been reported to produce a high percentage of responses with less toxicity than other combination treatments.
- Trial name
- NCT00078234
- Testing
- Oblimersen-rituximab-fludarabine
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Genta Incorporated
Hematologic Malignancy, GvHD
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell…
- Conditions
- Hematologic Malignancy, GvHD, GVHD,Acute, GVHD, Chronic
- Trial name
- NCT06462365
- Testing
- TRX103
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Tr1X, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.